Cognition Therapeutics (CGTX) Competitors $1.66 +0.44 (+36.07%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.62 -0.04 (-2.71%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ALEC, CRGX, AVTE, SOPH, ACIU, MNPR, HRTX, MDWD, VTYX, and NLTXShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Alector (ALEC), CARGO Therapeutics (CRGX), Aerovate Therapeutics (AVTE), SOPHiA GENETICS (SOPH), AC Immune (ACIU), Monopar Therapeutics (MNPR), Heron Therapeutics (HRTX), MediWound (MDWD), Ventyx Biosciences (VTYX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Its Competitors Alector CARGO Therapeutics Aerovate Therapeutics SOPHiA GENETICS AC Immune Monopar Therapeutics Heron Therapeutics MediWound Ventyx Biosciences Neoleukin Therapeutics Alector (NASDAQ:ALEC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Is ALEC or CGTX more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Alector's net margin of -142.10%. Alector's return on equity of -112.06% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alector-142.10% -112.06% -26.37% Cognition Therapeutics N/A -251.23%-130.75% Do insiders & institutionals believe in ALEC or CGTX? 85.8% of Alector shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 9.7% of Alector shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts prefer ALEC or CGTX? Alector currently has a consensus price target of $4.17, indicating a potential upside of 69.38%. Cognition Therapeutics has a consensus price target of $2.83, indicating a potential upside of 70.68%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29Cognition Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor ALEC or CGTX? In the previous week, Cognition Therapeutics had 4 more articles in the media than Alector. MarketBeat recorded 11 mentions for Cognition Therapeutics and 7 mentions for Alector. Cognition Therapeutics' average media sentiment score of 0.75 beat Alector's score of 0.40 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cognition Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ALEC or CGTX? Alector has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Which has stronger earnings and valuation, ALEC or CGTX? Cognition Therapeutics has lower revenue, but higher earnings than Alector. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$100.56M2.48-$119.05M-$1.16-2.12Cognition TherapeuticsN/AN/A-$33.97M-$0.67-2.48 SummaryCognition Therapeutics beats Alector on 10 of the 16 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.64M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-2.4820.4930.2825.74Price / SalesN/A356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book16.608.608.856.15Net Income-$33.97M-$54.65M$3.25B$265.06M7 Day Performance120.01%5.86%3.72%2.60%1 Month Performance192.25%8.86%5.86%2.83%1 Year Performance158.57%13.33%30.34%25.58% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.4595 of 5 stars$1.66+36.1%$2.83+70.7%+169.6%$89.64MN/A-2.4820Short Interest ↓Analyst RevisionHigh Trading VolumeALECAlector3.987 of 5 stars$2.23+3.7%$4.17+86.8%-49.4%$217.61M$100.56M-1.92270High Trading VolumeCRGXCARGO Therapeutics2.1194 of 5 stars$4.48-0.2%$15.40+243.8%-73.0%$217.16MN/A-0.97116Positive NewsAVTEAerovate TherapeuticsN/A$7.49+2.3%N/A-87.8%$217.10MN/A-2.5120High Trading VolumeSOPHSOPHiA GENETICS2.974 of 5 stars$3.01-5.3%$8.00+165.8%+0.0%$214.90M$65.17M-6.84520Short Interest ↓ACIUAC Immune1.8211 of 5 stars$2.07-3.3%$12.00+479.7%-35.3%$214.88M$31.02M-3.57140MNPRMonopar Therapeutics3.0791 of 5 stars$31.34-9.6%$60.00+91.4%+1,486.7%$211.89MN/A-9.0110News CoverageEarnings ReportAnalyst ForecastGap UpHRTXHeron Therapeutics4.1828 of 5 stars$1.28-3.0%$4.50+251.6%-27.4%$201.38M$144.29M-64.00300News CoverageEarnings ReportInsider TradeGap UpHigh Trading VolumeMDWDMediWound1.5584 of 5 stars$18.72+0.5%$32.25+72.3%+6.3%$201.35M$20.22M-8.9680News CoverageEarnings ReportVTYXVentyx Biosciences2.6506 of 5 stars$2.64-6.0%$10.00+278.8%+57.1%$200.38MN/A-1.5730NLTXNeoleukin TherapeuticsN/A$21.22-1.1%N/A-38.2%$199.43MN/A-6.8290News Coverage Related Companies and Tools Related Companies Alector Competitors CARGO Therapeutics Competitors Aerovate Therapeutics Competitors SOPHiA GENETICS Competitors AC Immune Competitors Monopar Therapeutics Competitors Heron Therapeutics Competitors MediWound Competitors Ventyx Biosciences Competitors Neoleukin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access